- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05133895
Pilot Study of Tocilizumab Monotherapy for Active Chronic Periaortitis
This is a prospective study to investigate the treatment response of Tocilizumab on patients with active chronic periaortitis (CP).
Methods: patients with a definite or possible diagnosis of CP at acute active stage were enrolled for this study and accepted Tocilizumab monotherapy for 3 months.
Endpoints: The primary endpoint is to investigate the treatment response of Tocilizumab; the secondary endpoints include the improvement of inflammatory markers, the frequency of adverse events.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Yunyun Fei
- Phone Number: +8613681125226
- Email: feiyunyun@pumch.cn
Study Locations
-
-
-
Beijing, China
- Yunyun Fei
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- adults ≥ 18 years of age at time of informed consent;
- meet clinical diagnostic criteria including (1) imaging findings show perivascular soft tissue density mass surrounding thoracic aorta, abdominal aorta or iliac arteries; (2) histopathological findings show fibrous tissue with chronic inflammatory infiltrate comprised of lymphocytes, plasma cells and macrophages (Neutrophils and granulomas are rare). Patients who satisfied (1) but without histopathological examination were perceived as possible CP;
- at active stage: clinical symptoms or organ involvement; a higher level of ESR and CRP than normal;
Exclusion Criteria:
- Secondary forms of CP related to drugs, infections, malignancies, Erdheim-Chester disease or other autoimmune diseases were excluded.
- Combined with other autoimmune diseases.
- Known immunodeficiency disorder.
- Pregnancy, lactation, or planning to become pregnant within 6 months of the test.
- Positive test for, or prior treatment for, hepatitis B or HIV infection. A positive test for hepatitis B is detection of hepatitis B surface antigen (HBsAg) or HBV-DNA.
- Evidence of active tuberculosis (TB), including Chest X-ray and PPD.
- Severe abnormal liver function or cardiac insufficiency.
- Any reason the investigator think that should not attend this trial.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Tocilizumab monotherapy
Patients with a definite or possible diagnosis of CP at acute active stage were enrolled for this study. Clinical diagnostic criteria consist of: (1) imaging findings show perivascular soft tissue density mass surrounding thoracic aorta, abdominal aorta or iliac arteries; (2) histopathological findings show fibrous tissue with chronic inflammatory infiltrate comprised of lymphocytes, plasma cells and macrophages (Neutrophils and granulomas are rare). Patients who satisfied (1) but without histopathological examination were perceived as possible CP. Secondary forms of CP related to drugs, infections, malignancies, Erdheim-Chester disease or other autoimmune diseases were excluded. Patients enrolled received intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months. |
intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
treatment response
Time Frame: three months
|
the rate of partial remission and complete remission after 3-month TCZ monotherapy
|
three months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the frequency of treatment related adverse events
Time Frame: three months
|
adverse events caused by TCZ during 3-month follow-up.
|
three months
|
the improvement of inflammatory markers
Time Frame: three months
|
including erythrocyte sedimentation rate (ESR) and high-sensitivity C-reactive protein (hsCRP).
|
three months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Tocilizumab for Periaortitis
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Periaortitis
-
Kamineni Institute of Dental SciencesCompletedIntrabony Periodontal Defect | Chronic Periaortitis
-
University of ParmaUnknownIdiopathic Retroperitoneal Fibrosis | Perianeurysmal Retroperitoneal Fibrosis | Chronic PeriaortitisItaly
-
Parker Research InstituteOak Foundation; Rehabilitation Center Rødovre Municipality (Genoptræning Rødovre... and other collaboratorsRecruitingChronic Disease | Chronic Conditions, Multiple | Chronic ConditionDenmark
-
Parker Research InstituteOak Foundation; Rehabilitation Center Rødovre Municipality (Genoptræning Rødovre... and other collaboratorsActive, not recruitingChronic Conditions, Multiple | Chronic ConditionDenmark
-
University of Alabama at BirminghamRecruitingDisability Physical | Chronic Conditions, Multiple | Chronic ConditionUnited States
-
Radboud University Medical CenterRecruitingChronic Conditions, Multiple | Chronic ConditionNetherlands
-
Documenting Hope ProjectRecruiting
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Korean Society of HematologyNot yet recruitingChronic Myeloid Leukemia, Chronic Phase
-
University of California, IrvineRecruitingChronic Myeloid Leukemia | Chronic Phase Chronic Myelogenous LeukemiaUnited States
Clinical Trials on Tocilizumab monotherapy
-
University of ChicagoActive, not recruiting
-
Xizang Haisco Pharmaceutical Co., LtdRecruiting
-
Masonic Cancer Center, University of MinnesotaActive, not recruiting
-
University of California, San FranciscoNot yet recruitingProstate Adenocarcinoma | Localized Prostate CarcinomaUnited States
-
CelltrionNot yet recruiting
-
University of ChicagoRecruiting
-
Reade Rheumatology Research InstituteZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruitingRheumatoid ArthritisNetherlands
-
Memorial Sloan Kettering Cancer CenterTerminatedCOVID-19United States
-
University of ChicagoCompleted
-
Karadeniz Technical UniversityCompletedCOVID-19 | Mortality | Critical Care | TocilizumabTurkey